EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors

Abdulhadi Jfri iD, Bonnie Leung, Jordan T Said, Yevgeniy Semenov iD, Nicole R LeBoeuf

Immunotherapy Advances · 01.01.2022 · 2 (1)

DOI: 10.1093/immadv/ltac016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 23.09.2022. Verfasst von Abdulhadi Jfri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Harvard Medical School, Boston, MA, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH, NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous immune-related adverse events (irAEs) are the most common irAEs caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both de novo and flares, may occur. Evidence is lacking on inverse psoriasis subtype.

Methods

A retrospective study was conducted at Dana-Farber Cancer Institute/Mass General Brigham through February 2020 using databases. Confirmed inverse psoriasis cases pre-/post-ICI initiation either independently or in conjunction with other psoriasis subtypes were included. Known psoriasis cases without flare post-ICI were excluded.

Results

A total of 262 (3%) individuals with any ICI-mediated psoriasiform cutaneous irAE were identified out of the 8683 DFCI ICI-treated patients. Of these, 13 (5% of psoriasis patients) had inverse psoriasis (mean age 68.7 years; 7/13 male sex). Median (range) time from ICI initiation to inverse psoriasis development or flare was 7 (4–12) and 3.5 (2–6) weeks, respectively. Pruritus occurred in 12/13 (92.30%) cases. 11 (85%) had inguinal involvement; other sites included gluteal cleft (6; 46%), inframammary (3; 23%), perianal (2; 15%), axilla (2; 15%), umbilicus (2; 15%), and infra-abdominal folds (1; 8%). Most (9/13) individuals had more than one site involved. The Common Terminology Criteria for Adverse Events severity was 1 in 10 (76.92%) individuals and 2 in 3 (15.38%) individuals. Six (46.15%) patients were treated initially by oncology with topical (nystatin, econazole, or clotrimazole) or systemic antifungals (fluconazole) for median (range) of 3.5 (1–7) months without improvement, for presumed candida intertrigo.

Conclusion

Patients on ICI may develop inverse psoriasis, which may be initially confused for fungal intertrigo. Delayed diagnosis can prolong symptoms, while patients are treated ineffectively with topical/systemic antifungals for presumed candida infection. Oncologist and dermatologist awareness is important to improve diagnosis of ICI-mediated inverse psoriasis, its management and affected patients’ quality of life.

Schlagwörter

Stichwörter der Autor:innen

flexural psoriasisimmune checkpoint inhibitorsimmune-related adverse eventsintertriginous psoriasisinverse psoriasisskin toxicity

Autor:innen und Institutionen

  • Dermatology Department, Harvard Medical School, Boston, MA, USA.
  • Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
  • Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Division of Dermatology, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
  • College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  • King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.

ORCID-Profile: Abdulhadi Jfri, Yevgeniy Semenov

Förderung

  • NCI NIH HHS
  • NIH
  • NCI

Zitieren

APA

Jfri, A., Leung, B., Said, J. T., Semenov, Y., & LeBoeuf, N. R. (2022). Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors. Immunotherapy Advances, 2(1). https://doi.org/10.1093/immadv/ltac016

Vancouver

Jfri A, Leung B, Said JT, Semenov Y, LeBoeuf NR. Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors. Immunotherapy Advances. 2022;2(1). doi:10.1093/immadv/ltac016

BibTeX
@article{Jfri2022,
  author = {Jfri, Abdulhadi and Leung, Bonnie and Said, Jordan T and Semenov, Yevgeniy and LeBoeuf, Nicole R},
  title = {Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors},
  journal = {Immunotherapy Advances},
  year = {2022},
  volume = {2},
  number = {1},
  doi = {10.1093/immadv/ltac016}
}
Kostenlos starten →